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 Williams-Beuren region reciprocal duplication 
 A significant recent finding in neurogenetics is the char-
acterization of the reciprocal duplication involving the Wil-
liams-Beuren syndrome (WBS, MIM194050) region. WBS 
is caused by genomic deletions in 7q11.23 that typically en-
compass 25–30 genes. WBS has the prevalence of 1/7,500 to 
1/20,000 and is among the most well-characterized micro-
deletion syndromes (Greenberg, 1990; Osborne, 1999; Tas-
sabehji, 2003). The majority of WBS patients carry a com-
mon recurrent 1.55 Mb deletion, which apparently occurs 
via non-allelic homologous recombination (NAHR) (Stan-
kiewicz and Lupski, 2002; Bayes et al., 2003). The reciprocal 
duplication of this deletion has long been expected; but it 
was not until 2005 that this duplication was finally identi-
fied in a single patient with severe speech delay (Somerville 
et al., 2005). Since then, 16 further duplications in the WBS 
critical region (WBCR) have been reported (Somerville et 
al., 2005; Kriek et al., 2006; Berg et al., 2007; Depienne et al., 
2007; Kirchhoff et al., 2007a; Torniero et al., 2007, 2008; 
Merritt and Lindor, 2008; Orellana et al., 2008), enabling 
the definition and the first characterizations of the 
dup(7)(q11.23) syndrome (MIM 609757).
 Abstract.  Several new genomic disorders caused by copy 
number variation (CNV) of genes whose dosage is critical 
for the physiological function of the nervous system have 
been recently identified. Dup(7)(q11.23) patients carry du-
plications of the genomic region deleted in Williams-Beur-
en syndrome, they are characterized by prominent speech 
delay. The phenotypes of Potocki-Lupski syndrome and 
 MECP2  duplication syndrome were neuropsychologically 
examined in detail, which revealed autism as an endophe-
notype and a prominent behavioral feature of these dis-
orders. Tandem duplication of  LMNB1  was reported to 
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cause adult-onset autosomal dominant leukodystrophy. 
 PAFAH1B1/LIS1 and  YWHAE,  which were deleted in iso-
lated lissencephaly ( PAFAH1B1/LIS1 alone) and Miller-
Dieker syndrome (both genes), were found to be duplicated 
in patients with developmental delay. Finally, two novel mi-
crodeletion syndromes affecting 17q21.31 and 15q13.3, as 
well as their reciprocal duplications, were also identified. In 
this review, we provide an overview of the phenotypic man-
ifestation of these syndromes and the rearrangements caus-
ing them.  Copyright © 2009 S. Karger AG, Basel 
 Much progress has been made in the research on CNV 
and neurological diseases since our last review on this topic 
(Lee and Lupski, 2006) two years ago. Some known disor-
ders were further characterized and several new genomic 
disorders with major neurological manifestations were 
identified, some of which are caused by rearrangements of 
genomic regions which were not related to any genomic dis-
order and others caused by rearrangements reciprocal to 
genomic intervals of known disorders. A few of these new 
findings are summarized and discussed in this review. Both 
autism and schizophrenia have been shown to be genomic 
disorders, they will be discussed elsewhere in this issue.
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of Health, the March of Dimes and the Charcot-Marie-Tooth Association. 
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 Phenotypic manifestations of dup(7)(q11.23) 
 Overall, dup(7)(q11.23) syndrome has milder and more 
variable manifestations compared to WBS. WBS patients 
have a distinctive and characteristic facial phenotype, 
whereas the dup(7)(q11.23) patients, though having some 
mild dysmorphology, do not share a common gestalt 
(Somerville et al., 2005; Kriek et al., 2006; Berg et al., 2007; 
Depienne et al., 2007; Kirchhoff et al., 2007a; Torniero et al., 
2007, 2008; Merritt and Lindor, 2008; Orellana et al., 2008). 
Most WBS patients display cardiovascular and connective 
tissue anomalies (the most common form being supraval-
cular aortic stenosis SVAS) resulting from haploinsufficien-
cy of the ELN gene inside WBCR ( Fig. 1 ) which codes for the 
protein elastin. Intragenic deletions and point mutations in 
 ELN have been found in patients with similar cardiovascu-
lar phenotypes but without WBS deletions, confirming  ELN 
 as the substrate of the cardiovascular components of WBS 
phenotypes (Morris and Mervis, 2000). Interestingly, no or-
gan anomalies were observed in most of the dup(7)(q11.23) 
patients. One potential explanation is that the development 
of the cardiovascular and connective tissues is only sensitive 
to decreased, but not to an abnormally increased dosage of 
 ELN . Alternatively, the variation in gene expression level is 
quantitatively not as significant when the  ELN  gene is 
changed from two copies to three copies in duplication pa-
tients instead of from two copies to one copy in the case of 
deletions.
 The most significant phenotypic component observed in 
almost all dup(7)(q11.23) patients is their moderate to severe 
language delay, paired with normal to only mildly impaired 
nonverbal and visuospatial skills (Somerville et al., 2005; 
Kriek et al., 2006; Berg et al., 2007; Depienne et al., 2007; 
Kirchhoff et al., 2007a; Torniero et al., 2007, 2008; Merritt 
and Lindor, 2008; Orellana et al., 2008). This pattern is the 
opposite of the typical WBS patients who display fluent ex-
pressive language alongside poor visuospatial skills (Mervis 
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 Fig. 1. Duplications in WBS region reported to date. The uppermost 
illustration of the WBS genomic region including genes, markers and 
LCRs is modified from Cusco et al. (2008). Red arrows in the middle of 
the figure demonstrate the common and uncommon recurrent dele-
tions of WBS. In the undermost part of the figure, solid green bars de-
pict the minimal duplicated regions according to the reports. The 
flanking dashed lines show the possible extensions to the maximal pos-
sible duplicated segment according to the available data. 
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and Klein-Tasman, 2000). This contrast is of extraordinary 
interest, as it indicates the existence of one or more genes in 
WBCR that are highly dosage sensitive (in case of both in-
creased and decreased gene amount) for the development of 
the neuronal circuits and pathways involved in human 
speech and language ability (Fisher, 2005; Tassabehji and 
Donnai, 2006). Moreover, speech delay is such a common 
general pediatric problem; other than sometimes being re-
lated to hearing impairment, there are relatively few insights 
into its biological causes.
 Mechanisms for the deletions and duplications in 
dup(7)(q11.23) 
 The WBS region displays a highly complex genomic 
structure; it contains three groups (A, B, C) of low copy re-
peats (LCRs) (Stankiewicz and Lupski, 2002) ranging from 
44 to 146 kb in size. Each group includes at least three high-
ly (up to 99.5%) homologous copies of LCRs which are local-
ized in three different modules (centromeric, medial and 
telomeric) (Cusco et al., 2008) ( Fig. 1 ). In 89% of WBS cases, 
the deletions are 1.55 Mb in length and arise via NAHR be-
tween the two LCRs Bc and Bm (Bayes et al., 2003; Cusco et 
al., 2008). An uncommon but recurrent deletion of 1.84 Mb 
has also been identified in 8% of WBS patients (Cusco et al., 
2008); this deletion is caused by NAHR between an alterna-
tive LCR pair Ac and Am (Bayes et al., 2003) ( Fig. 1 ). 
 Besides these two recurrent deletions, a number of non-
recurrent deletions of atypical sizes have also been identi-
fied (Wu et al., 1998; Botta et al., 1999; Tassabehji et al., 1999, 
2005; Korenberg et al., 2000; Gagliardi et al., 2003; Heller et 
al., 2003; Karmiloff-Smith et al., 2003; Howald et al., 2006; 
Schubert and Laccone, 2006). These atypical deletions, and 
the differences in their phenotypic manifestations, have 
been very informative in delineating the WBS endopheno-
types and especially in searching for genes associated with 
language and cognition (Tassabehji, 2003). Different from 
the two recurrent deletions, most of these nonrecurrent de-
letions do not have both breakpoints localized in LCRs, so 
they could have occurred via either non homologous end 
joining (NHEJ) (Shaw and Lupski, 2005) or replication fork 
stalling and template switching (FoSTeS) (Lee et al., 2007), 
as well as NAHR mediated by elements other than LCRs 
(such as the  Alu repeats; Babcock et al., 2003; Shaw and Lup-
ski, 2005). As little information on the exact breakpoints of 
these nonrecurrent deletions is available, no conclusion can 
be drawn yet as to which mechanism indeed causes these 
deletions. 
 Sixteen duplications in the WBS region have been report-
ed to date. The breakpoints of the two duplications described 
by Somerville et al. and Torniero et al. are localized in Bm 
and Bc ( Fig. 1 ); these two duplications are thus the bona fide 
reciprocal duplications of the 1.55 Mb WBS common recur-
rent deletion. The breakpoints of the duplications described 
in Kriek et al. (2006), Berg et al. (2007), Depienne et al. 
(2007), Kirchhoff et al. (2007a), Merritt and Lindor (2008), 
Orellana et al. (2008) and Torniero et al. (2008) were not ex-
actly mapped. They could be in any LCR or in the non-du-
plicated region between the LCRs Am and Bt; the duplica-
tions could thus be reciprocal to the common recurrent dele-
tion, uncommon recurrent deletion (if the breakpoints are 
in Ac and Am), or perhaps some may represent nonrecurrent 
duplications. The two duplications carried by case 4 report-
ed in Berg et al. (2007) and case 2 in Kriek et al. (2006) are 
clearly NOT reciprocal to the recurrent WBS deletions; one 
of them extends beyond WBCS into the telomeric direction, 
another one affects only one single gene  FKBP6  in WBCS. 
The identification of more duplications and the mapping of 
their breakpoints will help us further understand the mech-
anisms for these rearrangements. Furthermore, the pheno-
typic comparison among duplications with different sizes, 
as well as between reciprocal deletions and duplications will 
be very useful in further delineation of the dup(7)(q11.23) 
syndrome and understanding the substrates and pathways 
of the dosage sensitivity in the WBS critical region.
 Using a PCR-based sperm typing assay, Turner et al. 
(2008) mapped the frequency of the 1.55 Mb common WBS 
deletion and its reciprocal duplication in meiosis; they ob-
served a two deletion to one duplication ratio in the fre-
quencies of the reciprocal events. Considering the preva-
lence of WBS and the fact that the overwhelming majority 
of the WBS deletions are indeed due to the 1.55 Mb deletion, 
one should expect more duplication cases to be found soon. 
However, the phenotype of dup(7)(q11.23) syndrome seems 
to be much milder and does not include the multiple organ 
anomalies observed in WBS; the chance that these individ-
uals are medically ascertained and receive comprehensive 
genetic tests is thus lower than that for the WBS patients. 
 Flanking CNVs and SVs associated with the deletions 
and duplications in dup(7)(q11.23) 
 Only a few cases of parental inheritance have been re-
ported for the WBS deletion; otherwise, almost all WBS de-
letions are sporadic de novo events occurring in the meiosis 
of one of the parents (the transmitting progenitor) (Cusco 
et al., 2008). Several structural variants of the WBS region 
were observed to be frequently associated with the trans-
mitting progenitors. A 2 Mb inversion mediated by the in-
versely oriented centromeric and telomeric LCR modules, 
and including the whole WBCR, occurs more frequently in 
the transmitting parents than non-transmitting parents 
and control persons (Osborne et al., 2001; Bayes et al., 2003). 
An inversion does not change the copy number of genes and 
is not a true copy number variation (CNV); it is, however, a 
very important and frequent element of genomic structural 
variation (SV), as also observed by disease-independent ge-
nome-wide analyses of structural variations (Flores et al., 
2007; Korbel et al., 2007; Kidd et al., 2008). Most recently, 
Cusco et al. (2008) identified several CNV polymorphisms 
of the LCR blocks, the most frequent ones being deletion 
and duplication of the centromeric LCRs mediated by 
NAHR between Cc and Cm. The deletion allele was found 
to be significantly more frequent in transmitting progeni-
tors than non-transmitting progenitors and control indi-
viduals. 
 In four of the 16 dup(7)(q11.23) cases described to date, 
not enough information on inheritance pattern is available. 
Cytogenet Genome Res 123:54–64 (2008) 57
Quite different from the sporadic nature of WBS, among the 
remaining 12 informative dup(7)(q11.23) cases, one inher-
ited the duplication from his father (Kriek et al., 2006); three 
from their mothers (Berg et al., 2007; Torniero et al., 2008); 
4/12 (33%) is astonishingly high compared to the familial 
WBS cases. This difference may be related to the milder 
phenotype of dup(7)(q11.23) compared to WBS (Berg et al., 
2007). It will be very interesting to investigate if the CNV 
alleles associated with the transmission of the deletions also 
occur in higher frequency in the transmitting progenitors 
of the duplications. The theoretical answer would be yes.
 MECP2 duplication syndrome 
 The X-linked gene  MECP2 located in Xq28 encodes the 
methyl-CpG-binding protein 2 (MeCP2). By functioning
as both a transcription activator and repressor, MeCP2 
 regulates the expression of a wide range of genes in CNS 
(Chahrour et al., 2008). Point mutations and intragenic de-
letions in  MECP2  have been found to be the major cause of 
the neurodevelopmental disorder Rett syndrome (RTT, 
MIM312750). In females, the manifestation of Rett syn-
drome includes stereotypic hand wringing, loss of speech, 
acquired microcephaly, mental retardation with autistic 
features, seizures, ataxia, and breathing dysrhythmias. The 
only males manifesting  bona fide Rett syndrome when car-
rying the same mutations are those with an 47, XXY karyo-
type (reviewed in Moretti and Zoghbi, 2006). Males with 
normal karyotype and carrying the same mutations causing 
Rett syndrome in females suffer from severe encephalopa-
thy and infantile death (Zeev et al., 2002). Hypomorphic 
mutations barely causing any phenotype in females cause 
mental retardation, tremors and a variety of neuropsychiat-
ric features in males (Meloni et al., 2000; Cohen et al., 2002; 
Kleefstra et al., 2002).
 A number of deletions involving  MECP2 have been iden-
tified in female patients with Rett syndrome and one male 
patient with severe neonatal encephalopathy (Schollen et 
al., 2003; Laccone et al., 2004; Ravn et al., 2005; Hardwick 
et al., 2007; Scala et al., 2007). Skewed X inactivation (SCI) 
was identified in some, but not all informative deletion pa-
tients. Although some deletions include a part of the down-
stream flanking gene IRAK1  (Laccone et al., 2004; Pan et 
al., 2006; Hardwick et al., 2007; Scala et al., 2007), most of 
them are intragenic and involve parts of exon 3 and/or exon 
4 of  MECP2 (Ravn et al., 2005); none of the larger ( 1 1 kb) 
deletions has been reported to be recurrent. Interestingly, 12 
of 21 nonrecurrent deletions with precisely mapped bound-
aries have one of their breakpoints in a 150 bp genomic re-
gion, which is also a hotspot for the smaller deletions (20–
500 bp) confined within exon 4 (reviewed in Hardwick et 
al., 2007). This phenomenon was named breakpoint group-
ing (Lee et al., 2006), it has been described for the nonrecur-
rent duplications at the Pelizeaus-Merzbacher Disease 
(PMD, MIM312080) locus (Lee et al., 2006) and the nonre-
current deletions at the Smith-Magenis syndrome (SMS; 
MIM182290) locus (Stankiewicz et al., 2003). Similar to 
these loci, the  MECP2 locus also occurs in a region with 
highly complex genomic architecture characterized through 
multiple LCRs (del Gaudio et al., 2006). The occurrence of 
breakpoint grouping further highlights the important roles 
of genomic architecture in the formation of genomic rear-
rangements.
 Recently, a number of genomic duplications involving 
 MECP2 have also been identified in males manifesting a 
progressive neurodevelopmental syndrome (Van Esch et al., 
2005; Meins et al., 2005; del Gaudio et al., 2006; Friez et al., 
2006; Bauters et al., 2008; Carvalho et al., submitted). The 
common phenotypes include severe to profound mental re-
tardation, poor speech development, infantile hypotonia, 
recurrent infections, epilepsy and progressive spasticity. 
Tavyev et al. (submitted), for the first time, performed de-
tailed neuropsychiatric examinations including Autism Di-
agnostic Observation Schedule (ADOS) and Autism Diag-
nostic Interview-Revised (ADI-R) on nine males carrying 
 MECP2 duplication and demonstrated that autism is a de-
fining feature of the  MECP2 duplication syndrome (Tavyev 
et al., submitted). The neuronal phenotype of  MECP2  du-
plication (MIM 300260) is thus remarkably similar to that 
of Rett Syndrome caused by loss of function of  MECP2 with 
both disorders displaying mental retardation and autism. 
Analyses at cellular and molecular levels, however, showed 
that the detailed pathomechanisms underlying the two syn-
dromes are completely different (Chahrour et al., 2008). In-
terestingly, neuropsychological examination of the mothers 
of the duplication patients, who are carriers of the duplica-
tion, showed that they display significant psychiatric symp-
toms including generalized anxiety, depression, and com-
pulsion that preceded the birth of their children, although 
a nearly 100% skewing of X inactivation favoring the dupli-
cation chromosome was observed (Tavyev et al., submit-
ted). However, the skewed X inactivation was measured in 
the blood and does not necessarily reflect what is occurring 
in the brain. 
 No recurrent  MECP2 duplication has been observed yet, 
the boundaries of the duplications are scattered around a 
3 Mb region flanking  MECP2. High-resolution array CGH 
and subsequent PCR experiments revealed that some of the 
duplications have complex structure (Bauters et al., 2008; 
Carvalho et al., submitted) and may have arisen via the 
 FoSTeS mechanism. FoSTeS has also been observed for re-
arrangements at the PMD locus, similarly localized in a 
highly complex genomic region (Lee et al., 2007). Surpris-
ingly, the duplications in the  MECP2 region always encom-
pass much larger genomic fragments than the deletions. 
The smallest duplication in the  MECP2 region identified to 
date is 154 kb (Carvalho et al., submitted) and involves at 
least the complete open reading frames of  IRAK1  and 
 MECP2 . This smallest duplication already exceeds the larg-
est  MECP2 region deletions reported to date (Ravn et al., 
2005; Hardwick et al., 2007).
 The difference in the size of  MECP2 region duplications 
and deletions is curious. It might be due to the different 
mechanisms underlying the origin of these rearrangements 
and reflects a true difference in the size of the deletions and 
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duplication in this region; alternatively, it can be related to 
phenotypic selection, as has been postulated for the PMD 
associated PLP1 ( proteolipid protein 1 ) duplications (Inoue 
et al., 2002). The rearrangements not observed may have an 
early lethal or extremely mild phenotype, keeping the car-
riers from being medically ascertained. Skewed-X inactiva-
tion, which has been observed in all duplication carriers and 
some deletion patients, may also play a role in the pheno-
typic manifestation of these rearrangements. 
 ADLD and  LMNB1 duplication 
 After Charcot-Marie-Tooth disease type 1A (CMT1A, 
MIM118220) (Lupski et al., 1991; Raeymaekers et al., 1991) 
and Pelizeaus-Merzbacher Disease (PMD, MIM312080) 
(Inoue, 2005), the adult-onset autosomal dominant leuko-
dystrophy (ADLD, MIM169500) became the third member 
in the group of demyelinating disorders that can be caused 
by abnormal gene dosage (Padiath et al., 2006). ADLD is a 
very rare (only five families have been reported worldwide), 
slowly progressive and fatal condition which manifests in 
the fourth to sixth decade of life (Schwankhaus et al., 1994). 
The characteristic early autonomic abnormalities include 
bowel/bladder dysfunction, impotence in male patients, de-
creased sweating and others. Later in the course of their 
disease, ADLD patients develop ataxia and signs of pyrami-
dal tract involvement (Brown et al., 1987). Symmetrical de-
myelination in the CNS can be found in MRI scans and 
neuropathological examination (Schwankhaus et al., 1988). 
If not for the symmetry, such lesions could be mistaken for 
those observed in multiple sclerosis.
 Via linkage analysis, Fu and colleagues identified a locus 
on 5q31 which is linked to ADLD in a five-generation kin-
dred (Coffeen et al., 2000). In another segregating kindred, 
ADLD was reported as being linked to 5q23 (Marklund et 
al., 2006). Later, Fu and colleagues detected a tandem dupli-
cation of a 170 kb genomic fragment at 5q31 that segregates 
with the disease in the ADLD family (Padiath et al., 2006). 
The duplication does not disrupt any known gene and en-
compasses the complete ORF of two genes, of them only 
 LMNB1 (encoding Lamin B1) is expressed in the brain. In-
deed, increased expression of  LMNB1 ,  at both RNA and 
protein levels, was found in brain tissue of the patients bear-
ing the duplication. Also, overexpressing human  LMNB1 or 
its  Drosophila orthologue resulted in neurodegenerative 
phenotypes in flies. It is thus highly likely that the duplica-
tion of LMNB1 is causative for ADLD. 
 Lamin B1 is a member of the intermediate filament fam-
ily of proteins and is part of the nuclear lamina underlying 
the nuclear envelope of eukaryotic cells (Worman and 
Bonne, 2007). Mutations in its close paralogue,  LMNA/C , 
have been found to be causative for more than ten different 
disorders. Interestingly, some of the conditions result from 
haploinsufficiency of  LMNA (Worman and Bonne, 2007). 
Time-lapse videomicroscopy showed that the protein La-
min B1 serves a fundamental role within the nuclear enve-
lope by anchoring the nucleus to the cytoskeleton (Ji et al., 
2007). Silencing of  LMNB1  via  si RNA causes cell death in 
human cells and  C. elegans (Liu et al., 2000; Harborth et al., 
2001). Homozygous  Lmnb1 knockout mice die at birth, with 
defects in lung and bone (Vergnes et al., 2004). Intriguingly, 
the heterozygous knockout mice were reported to be fertile 
and ‘phenotypically indistinguishable from wildtype mice’ 
(Vergnes et al., 2004). It is not known how the increased dos-
age of Lamin B1 causes the phenotypes in ADLD.
 Duplication in the 17p13 lissencephaly and
Miller-Dieker syndrome region 
 Heterozygote deletions in the chromosomal region 17p13 
have long been known to cause two distinct disorders with 
partially overlapping phenotypes: isolated lissencephaly se-
quence (ILS, MIM607432) and Miller-Dieker syndrome 
(MDS, MIM 247200). Analyses of the phenotype-genotype 
associations of these two disorders (Cardoso et al., 2003) 
have highlighted the importance of two genes for the phe-
notypic manifestation of the deletion:  PAFAH1B1/LIS1  and 
YWHAE  (coding for the protein 14-3-3  ). The deletions in-
volving only PAFAH1B1/LIS1 (Reiner et al., 1993) but not 
 YWHAE cause ILS, characterized by lissencephaly and 
minimal or no other dysmorphic features (Cardoso et al., 
2003). ILS can be also caused by point mutations in the 
 PAFAH1B1/LIS1 gene (Uyanik et al., 2007). When the dele-
tion encompasses both  PAFAH1B1/LIS1 and  YWHAE , MDS 
is manifested, with lissencephaly plus significant facial dys-
morphism, as well as occasionally other congenital anoma-
lies (Dobyns et al., 1991). In addition, the lissencephaly phe-
notype in MDS is in general more severe than in ILS (Dobyns 
et al., 1991; Cardoso et al., 2003). Interestingly, two patients 
carrying deletions of only  YWHAE but not  PAFAH1B1/LIS1 
have also been reported, who have no lissencephaly, but 
only mental retardation (Cardoso et al., 2003).
 PAFAH1B1/LIS1 encodes a 45-kDa noncatalytic subunit 
of  p latelet- a ctivating  f actor  a cetyl h ydrolase 1B (Hattori et 
al., 1994).  YWHAE , or  14-3-3  , encodes the   isoform of the 
14-3-3 proteins, which bind to phosphoserine/phosphothre-
onine motifs in numerous binding partners and play impor-
tant roles in a multitude of cellular functions (Kjarland et 
al., 2006). PAFAH1B1/LIS1 and YWHAE/14-3-3  function 
in the same physiological pathway affecting neuronal mi-
gration (Toyo-oka et al., 2003; Wynshaw-Boris, 2007). Re-
duced dosage of either Pafah1b1/Lis1 or Ywhae/14-3-3  in 
mouse results in neuronal migration defects and develop-
ment impairments. The phenotypes are more severe in dou-
ble heterozygous knockout mice ( Pafah1b1 +/–, Ywhae +/–) 
when the dosage of both genes is decreased (Toyo-oka et al., 
2003), which is consistent with the human data.
 Interestingly, Mei et al. also reported a heterozygous du-
plication in PAFAH1B1/LIS1 in a patient with lissencephaly 
grade 2 (Mei et al., 2008). This duplication only includes 
exon 3–5 of  PAFAH1B1/LIS1 and likely disrupts its ORF and 
reduces the effective gene dosage. The pathological effect of 
this duplication would be thus probably similar to that of 
the loss-of-function deletions in  PAFAH1B1/LIS1. Duplica-
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tions truly increasing gene dosages were only detected very 
recently. Applying array CGH techniques, Bi et al. (2009) 
detected heterozygote duplication of either  PAFAH1B1/LIS1 
or  YWHAE / 14-3-3   alone, as well as a large duplication in-
volving both  YWHAE / 14-3-3   and  PAFAH1B1/LIS1 in sev-
en unrelated cases. RT-PCR confirmed the enhanced ex-
pression level of these two genes at increased gene dosage. 
Increased  PAFAH1B1/LIS1 dosage causes failure to thrive, 
moderate to severe developmental delay, small brain and 
mild brain structural abnormalities. Duplication of 
 YWHAE/14-3-3   is associated with dysmorphic faces, mac-
rosomia and developmental delay. None of the duplication 
patients showed a lissencephaly phenotype. Bi et al. also 
showed that transgenic mice overexpressing  Pafah1b1/Lis1 
mimicked part of the phenotypes observed in human, con-
firming the dosage-sensitivity of  PAFAH1B1/LIS1 at both 
decreased and increased expression. 
 The size and localization of most ILS and MDS deletions 
were analyzed via FISH (Cardoso et al., 2003; Chabchoub et 
al., 2006; Mei et al., 2008) and sequence-tag mapping (Car-
doso et al., 2003), only one case was analyzed with BAC-ar-
ray (Chabchoub et al., 2006). These methods are not optimal 
for detecting complex rearrangements or to map the exact 
boundaries of the rearrangements. It is thus not possible to 
conclude if the cases with similar deletions (Cardoso et al., 
2003) indeed represent recurrent rearrangements. Mei et al. 
obtained the breakpoints of deletions in four lissencephaly 
patients via long-range PCR (Mei et al., 2008). All obtained 
breakpoints are localized in or adjacent to  Alu sequence. 
Sequence analysis showed that two of the deletions probably 
occurred via  Alu -mediated NAHR, with one of them found 
in two patients, as has been previously shown for nonrecur-
rent SMS deletions in 17p11.2 (Shaw and Lupski, 2005). It is 
not clear from the reported data if it is a true recurrent dele-
tion or if these two patients inherited this deletion from a 
common ancestor. Another deletion apparently resulted 
from an NHEJ mechanism, with no homology found at the 
junction but a piece of ‘filler-DNA’ of 24 bp (Mei et al., 2008). 
The high-density oligo array with 2–3 oligos interrogating 
each kb DNA as well as subsequent PCR reactions enabled 
Bi et al. to observe several complex rearrangements with the 
duplications interrupted by triplication or normal copy 
number. These complex rearrangements are likely the result 
of the recently proposed replication Fork Stalling and Tem-
plate Switching (FoSTeS) mechanism (Lee et al., 2007). 
Breakpoint analyses are being performed for further infor-
mation regarding the mechanisms underlying these rear-
rangements.
 17q21.31 microdeletion syndrome 
 A new genomic disorder affecting the nervous system, 
the microdeletion syndrome 17q21.31 (MIM 610443) was 
identified by three groups simultaneously in 2006 (Koolen 
et al., 2006; Sharp et al., 2006; Shaw-Smith et al., 2006), after 
several single cases with similar deletions had been report-
ed earlier (Park et al., 1992; Khalifa et al., 1993; Varela et al., 
2006). In a recent multi-center clinical and molecular study 
on 22 patients, Koolen et al. (2008) estimated the prevalence 
of the 17q21.31 microdeletion syndrome to be 1/16,000. 
Common phenotypes observed in almost all affected indi-
viduals include developmental delay, hypotonia, a friendly/
amiable behavior and mild but characteristic dysmorphic 
facial features (Koolen et al., 2006, 2008; Sharp et al., 2006; 
Shaw-Smith et al., 2006). The deletions are of 500–650 kb in 
size; the minimal critical region was refined to a 424 kb ge-
nomic segment (Sharp et al., 2006; Koolen et al., 2008) and 
encompasses six genes including  CRHR1 (coding for corti-
cotrophin releasing hormone receptor 1) and  MAPT (cod-
ing for microtubule-associated protein tau), both highly ex-
pressed in brain (Sharp et al., 2006). Gain-of-function mu-
tations in  MAPT are known to cause autosomal dominant 
forms of frontal temporal dementia with parkinsonism 
(MIM 600274) (Hutton et al., 1998; D’Souza et al., 1999; 
Rademakers et al., 2004); common genetic variation of 
 MAPT is associated with progressive supranuclear palsy 
(PSNP, MIM 601104) (Pittman et al., 2005) and Alzheimer’s 
disease (Myers et al., 2005). Haploinsufficiency of  MAPT 
has never been reported in humans before (Koolen et al., 
2006). Interestingly, in mice lacking the  Tau/Mapt  gene 
(Harada et al., 1994), muscle weakness, hyperactivity in a 
novel environment and impairment of contextual fear con-
ditioning were found (Ikegami et al., 2000), in parallel to the 
motor developmental defect and learning disability ob-
served in del(17)(q21.31) patients (Koolen et al., 2006; Shaw-
Smith et al., 2006). These data render a possible role of 
 MAPT  in the pathomechanisms underlying this new ge-
nomic disorder microdeletion 17q21.31.
 The deletions in 17q21.31 always occur de novo; their 
breakpoints were mapped in large flanking LCR blocks of 
highly complex structure (Koolen et al., 2006; Sharp et al., 
2006; Shaw-Smith et al., 2006). Two major haplotypes 
named H1 and H2 exist for this region (Stefansson et al., 
2005). The H2 lineage harbors a 900 kb inversion covering 
the 17q21.31 deletion region and is under positive selection 
in European populations, where it has a frequency of 20%. 
One of the profound differences between these two haplo-
types is that the inversion places the two LCRs directly me-
diating the 17q21.31 deletions in the same orientation and 
thus facilitates/enables the NAHR rearrangements (Stankie-
wicz and Lupski, 2002) which delete the flanked interval 
(Lupski, 2006; Sharp et al., 2006). Indeed, haploype analyses 
in all three reports found that the transmitting parent of the 
deletion patient obligatorily carries either H1/H2 heterozy-
gote or H2/H2 homozygote genotype. No transmitting par-
ent without the H2 haplotype has ever been identified.
 Interestingly, a duplication of the critical region deleted 
in the 17q21.31 deletion syndrome has also been identified 
in a girl with severe psychomotor developmental delay and 
dysmorphic craniofacial features (Kirchhoff et al., 2007b). 
Like the transmitting parents of the deletion patients, the 
transmitting father of this girl also carries the H2 haplotype 
(H1/H2 heterozygote) (Kirchhoff et al., 2007b). It would be 
very interesting to compare the phenotype of the duplica-
tion patients with the patients carrying isolated gain-of-
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function mutations in  MAPT in detail, to evaluate the con-
tribution of  MAPT  to the duplication phenotypes. However, 
this comparison would be much more informative after 
more duplication patients are described and more precise 
knowledge can be gained about the phenotypic manifesta-
tion of the 17q21.31 duplication.
 15q13.3 microdeletion syndrome 
 Using their BAC array specifically designed to interro-
gate genome-wide 130 NAHR candidate sites flanked by 
LCRs (Sharp et al., 2005, 2006), Sharp et al. (2008) identified 
another new genomic disorder, the microdeletion syndrome 
15q13.3 (MIM612001), which is associated with mild to 
moderate mental retardation, seizure and/or abnormal EEG 
findings, mild and variable facial and digital dysmorphism. 
The recurrent deletion is 1.5 Mb long and encompasses six 
genes. The proximal and distal breakpoints of the deletions 
are localized in two large LCR/SD blocks designated BP4 
and BP5, respectively (Sharp et al., 2008). These data, and 
the apparent recurrent nature of the deletions both suggest 
that these deletions in 15q13.3 are caused by NAHR medi-
ated by BP4 and BP5. 
 Although the genomic localization of the deleted region 
is adjacent to the common deletion region in Prader-Willi 
syndrome (PWS, MIM176270) and Angelman syndrome 
(AS, MIM105830), none of the six included genes is known 
to be imprinted (Sharp et al., 2008). One of these genes, 
 CHRNA7 (cholinergic receptor, neuronal nicotinic, alpha 
polypeptide 7), encodes the alpha7 subunit of an ion chan-
nel, nicotinic acetylcholine receptor, that mediates neuronal 
signal transmission (Berg and Conroy, 2002).  CHRNA7 has 
been an interesting candidate gene for genetic epilepsies for 
many years; it is the paralogue of  CHRNA4,  the first gene 
ever found to be mutated in an idiopathic epilepsy syn-
drome, autosomal dominant nocturnal frontal lobe epilep-
sy (ADNFLE, MIM600513) (Steinlein et al., 1995). Muta-
tions in the gene coding for another subunit of the nicotin-
ic acetylcholine receptors, CHRNB2 (De Fusco et al., 2000; 
Phillips et al., 2001) and another paralogue of  CHRNA7 , 
 CHRNA2 (Aridon et al., 2006), were also found to cause 
epilepsy syndromes. Linkage studies pinpointed  CHRNA7 
as a possible susceptibility factor for both juvenile myoclon-
ic epilepsy type 2 (EJM2, MIM604827) (Elmslie et al., 1997) 
and benign epilepsy of childhood with centrotemporal 
spikes (MIM 117100) (Neubauer et al., 1997). Furthermore, 
knockout mice lacking  Chrna7 show a hypersynchronous 
neocortical EEG phenotype (Orr-Urtreger et al., 1997). 
However, pathological point mutations of  CHRNA7 have 
not been found in any epilepsy syndromes (Taske et al., 
2002; Ortrud Steinlein, personal communication). The 
finding of the microdeletion 15q13.3 syndrome now sheds 
new light onto  CHRNA7 and its possible role in epilepto-
genesis. Interestingly, a partial pseudogene of  CHRNA7, 
CHRFAM7A  is located less than 2 Mb away (Steinlein and 
Bertrand, 2008), not only adding difficulties to mutational 
analyses of  CHRNA7 , but also rendering the genomic archi-
tecture of this locus even more complex, as these two genes 
 CHRNA7  and CHRFAM7A  can function as substrates for 
NAHR themselves.
 Theoretically, the occurrence of the reciprocal duplica-
tion can be mostly expected for the region undergoing an 
NAHR-mediated recurrent deletion (Stankiewicz and Lup-
ski, 2002). Indeed, Sharp et al. identified an apparent recip-
rocal duplication of the 1.5 Mb deletion in a healthy control 
individual, indicating that the increased copy number of the 
critical genes in this region may not affect the neuronal sys-
tem in a way as dramatic as the decreased copy number 
(Sharp et al., 2008). Interestingly, the LCR/SDs in the two 
NAHR-mediating LCR blocks BP4 and BP5 have inversed 
orientation in the draft sequence of the UCSC sequence 
browser (www.genome.ucsc.edu). According to the mecha-
nisms of NAHR (Lupski, 1998; Stankiewicz and Lupski, 
2002), there is probably also an inverted haplotype in this 
region, which would place BP4 and BP5 into the same ori-
entation and facilitate the NAHR rearrangements. Indeed, 
this inversion was found in the transmitting progenitors of 
both 15q13.3 microdeletion carrying patients whose parent 
of origin could be determined. Further investigations are 
still needed for a statistically relevant conclusion because of 
the high frequency of this inversion in the normal popula-
tion.
 Conclusions 
 Since the 1998 review that coined and defined the term 
genomic disorders (Lupski, 1998), a multitude of genomic 
disorders caused by genomic rearrangements instead of the 
traditional Watson-Crick base pair changes have been iden-
tified. Many of these disorders are due to altered gene dos-
age, or copy number variation (CNV), of one or more dos-
age-sensitive genes inside the rearranged region. The recent 
development of new techniques such as array-CGH to ob-
serve the rearrangements and their breakpoints with a high-
er resolution have greatly facilitated and catalyzed the iden-
tification and characterization of CNVs and novel genomic 
disorders; they have also yielded insights into molecular 
mechanisms for the rearrangements as well as the biological 
nature of the dosage-sensitivity of the rearranged regions 
which result in diseases (reviewed by Lupski and Stankie-
wicz, 2005; Emanuel and Saitta, 2007; Stankiewicz and 
 Beaudet, 2007; Gu et al., 2008).
 In this review, we summarized some of the most recent-
ly defined genomic disorders affecting the nervous system. 
These disorders can be neurodevelopmental (as WBS and 
the reciprocal duplication), neurodegenerative (as ADLD), 
or neuropsychiatric diseases (as autism; Sebat et al., 2007; 
Kumar et al., 2008; Weiss et al., 2008; and schizophrenia: 
Lupski, 2008; Stefansson et al., 2008; The International 
Schizophrenia Consortium, 2008; Walsh et al., 2008; Xu et 
al., 2008) which are described elsewhere in this issue). From 
the rearrangement point of view, CNV-based genomic dis-
orders could be due to duplication, deletion or sometimes 
complex rearrangements including both events in different 
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genomic segments (Lee et al., 2007). The mechanisms un-
derlying  these  pathological rearrangements, as for any 
 other genomic rearrangements, can be NAHR, NHEJ or 
FoSTeS (Lupski and Stankiewicz, 2005; Lee et al., 2007; Gu 
et al., 2008). Not many publications have reported NHEJ or 
FoSTeS as the presumptive mechanism underlying a patho-
logical rearrangement, which is partially because the char-
acteristics of NHEJ and FoSTeS are not resolved by many 
traditional techniques and are not yet as well known among 
the geneticists as NAHR and are often not recognized, as in 
the case of the atypical nonrecurrent deletions in WBS de-
scribed in the first part of this review. High resolution ge-
nome analysis tools and direct sequencing of breakpoints 
are often required to reveal complex rearrangements. We 
expect to see more NHEJ- or FoSTeS-mediated pathological 
rearrangements reported in the future, especially in the 
analyses of the ‘atypical’ or nonrecurrent rearrangements.
 It should be emphasized that the identification of a new 
genomic disorder is by no means accomplished after the 
original finding of overlapping genomic rearrangements 
and common phenotypes at a certain genomic locus. The 
reciprocal duplications to the Smith-Magenis Syndrome de-
letions were already described by Potocki et al. (2000) as a 
new genomic disorder identified in seven individuals in 
2000, but it was not until 2007 that the same group and their 
collaborators have recruited more patients and performed 
comprehensive, multidisciplinary clinical and molecular 
analyses  on  35  patients  bearing  this duplication, thus giv-
ing the first comprehensive clinical description of this dis-
order, now named the Potocki-Lupski syndrome (PTLS, 
MIM610883) (Potocki et al., 2007). The clinical data refined 
the key phenotypes of PTLS, which include infantile hypo-
tonia, failure to thrive, mild to moderate mental retardation 
and autism spectrum disorders. It was not until this com-
prehensive clinical study with 35 patients that the autistic 
features and structural cardiovascular anomalies were also 
identified to be among the key manifestations of PTLS. The 
number of patients and the state-of-art array CGH tech-
nique also enabled the precise mapping of the rearrange-
ments and further delineations of the phenotypes, which 
narrowed down the critical region of PTLS to a 1.3 Mb re-
gion containing  RAI1 , the critical dosage-sensitive gene for 
SMS (Slager et al., 2003; Bi et al., 2004, 2006; Girirajan et al., 
2005). We look forward to similar developments in the re-
search of all newly defined genomic disorders, to the new 
clinical and biological insight that the future studies of these 
disorders will bring us. 
 For many genomic disorders with distinct abnormali-
ties, the reciprocal rearrangements have partially milder 
phenotypes (such as the facial dysmorphology in the recip-
rocal duplication of the WBS) or a reduced penetrance (as 
in the reciprocal duplication of the WBS deletion and the 
microdeletion 15q13.3 syndrome), implicating that dosage 
sensitivity does not always apply for both increased or de-
creased dosage of the same gene. In some other cases, the 
reciprocal rearrangements have partially opposite or recip-
rocal endophenotype (as the difference in the speech vs. vi-
suospatial development between WBS and dup(7)(q11.23) 
syndrome), indicating a quantitative read out system down-
stream of a critical gene. There are also instances when du-
plications and deletions involving the same gene manifest 
similar phenotypes, although through completely different 
molecular pathways, as in deletions and duplications of 
 MECP2 . Whether and how too much or too little gene prod-
uct will be recognized and/or tolerated by the organism is 
not a trivial fact, it reflects the function and regulation of 
an individual gene and the pathways in which it is involved. 
Careful analysis and comparison of the phenotypes of re-
ciprocal genomic disorders/conditions would thus likely 
provide interesting insight into the biology of the genes un-
derlying their pathomechanisms. 
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